VDP-86 [Assessment] Humanity - digital health app

One liner: Humanity is an app that uses wearable technology and quantified-self methods to enable anyone with a smartphone to measure their rate of aging and it uses AI to find out what lifestyle actions and more advanced interventions each type of user should take to slow it down: ”a Waze for longevity”.

Longevity Dealflow WG Team
Shepherd: Eli Mohamad
Other squad members: Laurence Ion, Paolo Binetti, Tuan Dinh, Alex Dobrin, Tim Peterson

Simple Summary
Humanity is a quantified-self app that enables users to connect physical wearables and activity apps that monitor digital biomarkers through a single interface. Users may manually add data as well and soon will be able to upload blood and genetic data. The data from all these sources is used to generate a proprietary score representing the rate of the user’s aging. Importantly, the app then helps users understand which activities and habits slow down or even reverse their current rate of aging. The company uses multiple established behavior modification tools to steer user behavior, and develops its own tools and biomarkers, with the goal of sourcing, distributing and guiding users to take better healthspan interventions over time.

VitaDAO collaboration potential beyond financing
Humanity uses “points” to reward users for actions. The Humanity team is very open to discussing what role $Vita may be able to play as a “longevity token” in or adjacent to the app. Such exploration would be in line with the VitaDAO Strategic Plan of 2023. For example, even just expanding our token users by 150k people (the current Humanity userbase) may be a great benefit to VitaDAO.

Problem and Opportunity
The development of drug or biologics-based therapies addressing chronic and other aging-related diseases is an extremely expensive and time-intensive endeavor. We are yet to see a drug or therapy that significantly extends the human healthspan. On the other hand, behavioral modifications such as diet, physical activity, sleep, and stress, have been shown to have an incredible impact on human healthspan. Exercise alone (in the form of weightlifting and aerobic activity), has been associated with a >40% decrease in all-cause mortality risk.

Instead of attacking chronic diseases one by one, Humanity is pursuing development and implementation of behavioral interventions that slow aging, potentially adding many more healthy years than any single drug or therapy that would cure any of the top chronic disease killers today.

The rate-of-aging scores are calculated by proprietary algorithms built on longitudinal data (External Biobank Database). The algorithms are improved by continuously combining data from existing users (Humanity Biobank Database), enabling the discovery of better metrics and better combinations of digital and physical biomarkers to eventually being able to increase the positive impact of interventions and behavioral modification. Behaviors are gamified based on points (in-game currency) as well as digital twins (i.e. what worked for “similar” users best), increasing user retention and activity.

Current traction reflects the perception of app utility by the (still) early users. With a 10% conversion to premium users, as well as 65% 12-week retention of premium users, the app’s metrics are significantly above industry numbers.

High retention may also be explained by the apparent success of Humanity’s behavioral modification tools. A clinically obese cohort (i.e. those that can gain most from behavioral modification) experienced an 18% (15.4% median for all active users) sustained increase in movement after signing up, over the lifespan of the observational study (80 days - 40 days before and 40 days after sign up to Humanity).

Intellectual property
Humanity endeavors to improve a “digital first” aging model they developed based on UK Biobank data and a partnership with Gero, which uses movement and heart rate patterns along with other attributes of the user to measure aging daily.

Possibly the most unique IP is the creation of a database of what actions and interventions are working in combination to reduce different types of people’s rates of aging. The combination of actions/interventions and what type of person each combination works for is information no other project currently has a reasonable ability to collect at scale. Humanity has the potential to reach hundreds of millions of users directly.

Future upgrades:
While the company’s focus remains on digital biomarkers, it aims to add genetic and blood monitoring services and already has those relationships set up with Illumina and Eurofins. The data gathered from these products (e.g. genotyping and DNA methylation), and combined with digital biomarkers, may yield yet additional IP.

The Humanity founding team are seasoned serial entrepreneurs who previously launched extremely successful digital consumer platforms and exited their companies. They are also reportedly long time supporters of the Longevity sector.

Peter Ward, CEO and co-founder
After starting his career in management consulting, Peter co-founded, built and ran the world’s largest social travel network for over 13 years: WAYN.com. After selling the company to lastminute.com group in 2016, Peter successfully launched and rolled out ContentHUB - a state-of-the-art site personalization CMS. He then grew WAYN revenues by 194%, and increased monthly visits by 55% in just 12 months post-acquisition.

Michael Geer, CSO (Chief Strategy Officer) and co-founder
Before co-founding Humanity, Michael was CSO/COO of AnchorFree, running one of the world’s most popular freedom and privacy digital platforms. Anchorfree apps grew by over 100M downloads in just 12 months, and approximately 400,000 people download an AnchorFree App every day. Michael helped the platform grow to 900M users. Previously, Michael was on the founding team of Badoo, and grew it into one of the largest dating sites worldwide. Badoo was sold for $3 bn.

The company has an advisory board of some of the world’s top scientists and thinkers, including Kristen Fortney (CEO of Bioage), George Church (HMS), Robert Green (HMS), Tonu Esko (Direct at Estonian Biobank) and Peter Joshi (CSO at Humanity Inc).

Humanity has previously raised $5M, and the team is currently raising $1M in a standard SAFE, of which $950k has been committed. VitaDAO could contribute the last $50,000 to close this round. The team anticipates starting to raise a ~5M Seed Round later in 2023.

The use of capital would be for development salaries, marketing, and operations.


  • Excellent team, with ample experience in growing the userbase for digital platforms
  • Grew to >150k users in 12 months
  • Appstore 4.8 rating with 2.5k ratings
  • Potential for making digital biomarkers as significant in chronic disease prediction as blood biomarkers, enabling earlier and more substantial interventions to extend healthspan
  • Captive audience for experimental interventions and tests
  • Freemium subscription has been shown to work in the quantified-self field


  • Highly competitive landscape - further exploration on strength of IP is needed
  • The team is yet to prove the ability to extend healthspan through more complex interventions in addition to increasing physical activity or extending fasting windows
  • Experimental plans yet to be developed


This proposal has been evaluated by 3 business experts and scientists, obtaining an average conviction score of 4/5. The reviewers agreed the biggest strength of the proposal is the team and the fact the company is open to experiment with $VITA. While engagement has seen a drop in the beginning of this year, it followed a large drop in marketing expenses. This is expected to reverse starting March.


Here we’ll vote if the Longevity-Dealflow WG’s assessment should go on-chain.

If it succeeds here, the VITA token holders will ratify the WG’s assessment (positive or negative) via a decentralized vote.

  • Agree
  • Revisions Requested (Detail in Comments)
  • Disagree

0 voters

1 Like

When would the SAFE come due? In the $5M round? Or is everyone about to get diluted out to $6M? Is there an advantage to waiting until the $5M round?

What are the other competitors?

Overall, I think either this app or a competitor app (aren’t Garmin, Google/Fitbit, Whoop, Oura all in this business too?) will have the biggest impact on life extension at scale.

Has the WG assessed the competition, and decided this is the best one, or is this the only one to come to VitaDAO? If we like the idea of digital apps, maybe we should aim to fund a few of them.


Thanks for the questions and comments! This is Michael Geer Co-Founder of Humanity. Will answer inline below:
"When would the SAFE come due? In the $5M round? Or is everyone about to get diluted out to $6M? Is there an advantage to waiting until the $5M round?
[MG] Yes, the SAFE would convert in the Seed round and at a 15% discount to the price of the round. As it is a small round size, most likely most will be taken by the lead investor and pro-rata for current investors. So getting in on this SAFE has those two big advantages.

What are the other competitors?
[MG] Competitors for general market share are mostly wellness apps as they appear in searches when a user goes to the app stores looking to be healthier. None at the moment are using the new paradigm of driving things on predictive models built on longitudinal health data and the Waze method of actually watching all the actions/interventions people are trying and see how they move this predicted future health endpoint. Also, our true focus is collaboration and moving the Longevity field forward, so we will be an agnostic distributor and tester of other tests that are development and importantly all the interventions that are developed.

Overall, I think either this app or a competitor app (aren’t Garmin, Google/Fitbit, Whoop, Oura all in this business too?) will have the biggest impact on life extension at scale.
[MG] Definitely agreed. The nuance I would add is that we plan to distribute pills and other interventions eventually, as well, if the data and safety of these interventions is proven to a sufficient level. So measuring impact and in combination with other interventions and for who - as you say will be done at scale through Humanity and Humanity like systems, and the interventions that can be distributed and measured are limitless and make up some of the other projects being funded by this great DAO.

Has the WG assessed the competition, and decided this is the best one, or is this the only one to come to VitaDAO? If we like the idea of digital apps, maybe we should aim to fund a few of them."
[MG] I can’t speak to the first question, but agreed that more funding for projects that can help increase people’s healthspan today is definitely part of what I would consider a healthy mix of projects VitaDAO should put up for proposal and vote for.


Thanks, @bowtiedshrike! Regarding the last question - we have assessed the competition, and Humanity is not the only one that we had conversations with about potential funding. Their goals fit well within our mission, and they are openly pro-longevity rather than performance alone. The collaboration potential on the token utility is also a great benefit. We’ll continue to assess other apps as well.


Could make sense to explore collaborations and integrations independent of an investment though in my view. Am 100% sympathetic to the former, and somewhat unsure if we should do investments in apps etc., as the marginal impact trends towards 0 with other willing funders, would rather have Vita fund more early stage research, although i’m a big fan of the humanity app and team!!


Thanks for the comment, Vincent! So my obviously seemingly biased view (as I cofounded the horse in this particular race :)), but hopefully balanced by my longterm belief and support in the longevity mission, is that I think VitaDAO can do more than fill what may be seen as a hole in early funding for longevity research. As Aubrey has spoken about a lot, once people get a taste and belief that something can be done about longevity, the wave will really break and funding will flood in. The issue is that if all the main focus is on earlier research, the public does not get to that point as soon. There needs to be a portion of the investments and projects in the space focusing on bringing the idea and reality that we can slow our aging to the masses now. In short, there may be a step function increase in funding for the space that we can trigger with more awareness caused by getting more people measuring and slowing their aging already today.

Second thought, maybe closer to your comment, is it may be worth considering a more balanced portfolio strategy (including investments that may pay off sooner, are popular already, and ones outside of IP, etc.) so the DAO treasury starts to build up a more consistent stream of revenue over the next few years.

All this being said, I’m sure you guys have thought about the different angles quite a bit, so will look forward to a more comprehensive catch up on that soon!


Great points, and def agree that some of our money should flow into areas that are consumer facing or paying off sooner.


This proposal has passed phase 3 and is being implemented by the DAO